Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
Executive Summary
Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.
You may also be interested in...
French Biotech Valneva Raises $51 Mil. And Aims For Profitability In 2015
The new European biotech aims to become a profitable niche player focused on anti-infective vaccines and antibodies in 2015.
Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry
One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.
Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.